CA2205138A1 - Anticorps humains pour les peptides recepteurs de lymphocytes t et leur methode de preparation - Google Patents

Anticorps humains pour les peptides recepteurs de lymphocytes t et leur methode de preparation

Info

Publication number
CA2205138A1
CA2205138A1 CA002205138A CA2205138A CA2205138A1 CA 2205138 A1 CA2205138 A1 CA 2205138A1 CA 002205138 A CA002205138 A CA 002205138A CA 2205138 A CA2205138 A CA 2205138A CA 2205138 A1 CA2205138 A1 CA 2205138A1
Authority
CA
Canada
Prior art keywords
antibodies
human
bind
tcr
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002205138A
Other languages
English (en)
Inventor
Douglas F. Lake
William J. Landsperger
John J. Marchalonis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter International Inc
University of Arizona
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2205138A1 publication Critical patent/CA2205138A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Préparations d'anticorps humains enrichies pour obtenir des anticorps qui se lient avec les peptides de récepteurs de lymphocytes T humains ou aux déterminants de conformation. L'invention décrit également les méthodes de préparation de ces anticorps à partir de fractions du plasma humain selon Cohn, par purification d'immunoaffinité, à l'aide de protéines de récepteur de lymphocytes T de recombinaison ou de peptides à région variable de récepteurs de lymphocytes T. La purification des anticorps de récepteurs de lymphocytes T à partir de mélanges d'anticorps humains ou animaux est effectuée suivant des procédures d'immunoaffinité qui font appel à des protéines de récepteurs de lymphocytes T humains de recombinaison. Les anticorps purifiés par immunoaffinité peuvent se fixer sur les récepteurs de lymphocytes T intacts liés à la membrane grâce à une sélection des cellules reposant sur la fluorescence et peuvent aussi inhiber la prolifération des lymphocytes T suite à une stimulation par le mithogène. Les anticorps polyclonaux humains purifiés par immunoaffinité peuvent inhiber l'activité lytique des cellules tueuses naturelles sur une ligne de lymphocyte T monoclonaux. Les préparations d'anticorps sont susceptibles d'être utilisées pour diagnostiquer, surveiller et soigner différents syndromes de maladies auto-immunes.
CA002205138A 1994-11-16 1995-11-15 Anticorps humains pour les peptides recepteurs de lymphocytes t et leur methode de preparation Abandoned CA2205138A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34115794A 1994-11-16 1994-11-16
US08/341,157 1994-11-16

Publications (1)

Publication Number Publication Date
CA2205138A1 true CA2205138A1 (fr) 1996-05-23

Family

ID=23336462

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002205138A Abandoned CA2205138A1 (fr) 1994-11-16 1995-11-15 Anticorps humains pour les peptides recepteurs de lymphocytes t et leur methode de preparation

Country Status (5)

Country Link
EP (1) EP0792294A1 (fr)
JP (1) JPH10509948A (fr)
AU (1) AU705010B2 (fr)
CA (1) CA2205138A1 (fr)
WO (1) WO1996015153A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9904395D0 (en) * 1999-02-25 1999-04-21 Fluorescience Ltd Protein assay
US6972198B2 (en) 1999-02-26 2005-12-06 Cyclacel, Ltd. Methods and compositions using protein binding partners
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
AT410636B (de) * 2001-03-23 2003-06-25 Igeneon Krebs Immuntherapie Verfahren zur herstellung eines impfstoffes
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
EP1532983A1 (fr) 2003-11-18 2005-05-25 ZLB Bioplasma AG Preparation d'immunoglobulines à stabilité élevée
WO2011095543A1 (fr) 2010-02-04 2011-08-11 Csl Behring Ag Préparation d'immunoglobuline
EP2361636A1 (fr) 2010-02-26 2011-08-31 CSL Behring AG Préparation d'immunoglobuline et système de stockage pour préparation d'immunoglobuline
WO2013132347A2 (fr) * 2012-03-06 2013-09-12 Calpro As Immunodosage elisa amélioré de la calprotectine
ES2745472T3 (es) 2013-07-15 2020-03-02 The U S A As Represented By The Secretary Department Of Health And Human Services Office Of Tech Tra Receptores de células T anti-virus del papiloma humano 16 E6
ES2988823T3 (es) 2014-12-03 2024-11-21 Csl Behring Ag Producto farmacéutico con mayor estabilidad que comprende inmunoglobulinas
US10221249B2 (en) 2015-09-10 2019-03-05 Affigen, Llc Method of making patient specific anti-idiotype antibodies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2018248A1 (fr) * 1989-06-07 1990-12-07 Clyde W. Shearman Anticorps monoclonaux contre le recepteur alpha-beta de cellules t humaines, leur production et leur utilisation
WO1991016910A1 (fr) * 1990-05-03 1991-11-14 Systemix, Inc. Tissu lymphoide humain utilise chez un hote presentant un deficit immunitaire

Also Published As

Publication number Publication date
EP0792294A1 (fr) 1997-09-03
JPH10509948A (ja) 1998-09-29
AU4161196A (en) 1996-06-06
AU705010B2 (en) 1999-05-13
WO1996015153A1 (fr) 1996-05-23

Similar Documents

Publication Publication Date Title
US5223426A (en) Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor
Chang et al. Monoclonal antibodies specific for human IgE-producing B cells: a potential therapeutic for IgE-mediated allergic diseases
EP0307434B2 (fr) Anticorps alteres
US5543144A (en) Treating hypersensitivities with anti-IGE monoclonal antibodies which bind to IGE-expressing B cells but not basophils
US6790938B1 (en) Anti-GPIIb/IIIa recombinant antibodies
AU724856B2 (en) Anti-Fas ligand antibody and assay method using the anti-Fas ligand antibody
Wilson et al. Monoclonal antibodies to the 140,000 mol wt glycoprotein of B lymphocyte membranes (CR2 receptor) initiates proliferation of B cells in vitro
EP0547137A1 (fr) Immunoglobulines homoconjuguees
JPH07126300A (ja) ヒトのｂ細胞受容体複合体の特異抗原を認識するモノクローナル抗体
JP2007045843A (ja) 炎症性胃腸病の処置
CA2205138A1 (fr) Anticorps humains pour les peptides recepteurs de lymphocytes t et leur methode de preparation
Gergely et al. Chemical Analyses of Variable Regions of Heavy and Light Chains of Cold Agglutinins 1
JPH01501201A (ja) 抗体
Spurll et al. A family of T-cell alloantigens linked to Igh-1
Adib-Conquy et al. Monoclonal IgG and IgM autoantibodies obtained after polyclonal activation, show reactivities similar to those of polyclonal natural autoantibodies
EP0503646A1 (fr) Anticorps monocloneaux dressés contre l'antigène-3 associé à la fonction lymphocyte
EP0511308B2 (fr) Immunoglobuline chimerique pour recepteurs de cd4
WO1994028023A1 (fr) Proteine de membranes cellulaires exprimee par les thymocites du cortex humain, et son emploi
Lake et al. Characterization of autoantibodies directed against T cell receptors
Elagib et al. Characterization and VH sequences of human monoclonal anti-F (ab′) 2 autoantibodies from normals and Sjögren's syndrome patients
US20010051709A1 (en) Chimeric immunoglobulin for CD4 receptors
Mouawad et al. Antibodies raised against peptide fragments of CD16 reacting with membrane and soluble form of CD16. I: Production and characterization
BUJANOWSKI 0.1 Expression of FCE-Receptor II (CD23) and release of IgE-binding factors (IgE-BF) from lymphoblastoid cell line RPMI 8866 and
CA2005121A1 (fr) Reactif d'anticorps monoclonaux avec des regions definies des recepteurs d'antigenes des cellules t
IL108742A (en) Active monoclonal antibodies with defined regions of the T cell antibody receptor

Legal Events

Date Code Title Description
FZDE Dead